close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

24.46 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
30 31 Next >
FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse
The FTC is investigating Teva Pharmaceuticals for alleged misuse of inhaler patents to block generic competition and maintain high prices in the U.S. while selling the same products for less overseas. 
Via Benzinga
Topics Intellectual Property
Dr. Reddy's Labs Stock Sees Improved Technical Strength
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. 
Via Investor's Business Daily
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
From Teva Pharmaceutical Industries Limited
Via Business Wire
Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views
 
Via Benzinga
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
From Teva Pharmaceutical Industries Limited
Via Business Wire
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
 
Via Benzinga
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
 
Via Benzinga
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Engages In Settlement Talks Over Medicare Kickback Allegations
Teva Pharmaceutical is negotiating with the DOJ to settle a lawsuit alleging it paid kickbacks through charities to boost Copaxone sales, risking up to $10 billion in damages. 
Via Benzinga
Topics Lawsuit
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly... 
Via Benzinga
Topics Lawsuit
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
What is a Bull Flag Pattern? Explanation and Examples
Learn how to identify and trade the bull flag pattern, which is a key tool for spotting continuations in bullish trends. 
Via MarketBeat
Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know
 
Via Benzinga
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
2 Generic Drug Makers With Growing Runways
Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. 
Via MarketBeat
Topics Intellectual Property
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Alvotech
Via GlobeNewswire
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
From Teva Pharmaceutical Industries Limited
Via Business Wire
These 10 Large Cap Stocks Shined Brightest Last Week (May 5-May 11, 2024): Are They In Your Portfolio?
Toast, Teva, Vistra, Equinix, Applovin, IFF, Constellation, Emerson, IP, and STERIS were top performers last week. Are they in your portfolio? 
Via Benzinga
These 7 Stocks Surged Double-Digits and Have Double-Digits to Go
Stocks surging on earnings reports often continue moving higher over time. This is a look at seven that surged more than 10% on Q1 results. 
Via MarketBeat
Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript
TEVA earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzapine release. Clinically meaningful improvements in PANSS scores observed... 
Via Benzinga
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
 
Via Benzinga
TEVA Stock Earnings: Teva Pharmaceutical Indus Misses EPS, Beats Revenue for Q1 2024
TEVA stock results show that Teva Pharmaceutical Indus missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today